Survivors of childhood, adolescent, and young adult cancer, previously treated with
anthracycline chemotherapy (including mitoxantrone) or radiotherapy in which the heart was …

Cardiac diseases in the growing population of childhood cancer survivors are of major
concern. Cardiotoxicity as a consequence of anthracyclines and chest radiotherapy …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

PURPOSE For survivors of childhood cancer treated with doxorubicin, dexrazoxane is
cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS …

Background Cardiotoxicity is among the most important adverse effects of childhood cancer
treatment. Anthracyclines, mitoxantrone and radiotherapy involving the heart are its main …

Aims Childhood cancer therapy is associated with a significant risk of therapy‐related
cardiotoxicity. This meta‐analysis aims to evaluate cardiac biomarkers for the detection of …

Background: Anthracycline-induced cardiotoxicity is a major cause of morbidity and mortality
in childhood cancer survivors (CCSs). Echocardiographic myocardial strain imaging is …

Innovative therapeutic strategies in childhood cancer led to a significant reduction in cancer-
related mortality. Cancer survivors are a growing fragile population, at risk of long-term side …

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of
cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases …

Background Survivors of childhood cancer exposed to cardiotoxic therapies are at
significant cardiovascular risk. The utility of cardiac biomarkers for identifying the risk of …